Celldex Therapeutics (NASDAQ:CLDX) Rating Reiterated by Cantor Fitzgerald

Celldex Therapeutics (NASDAQ:CLDX)‘s stock had its “overweight” rating reissued by equities researchers at Cantor Fitzgerald in a note issued to investors on Tuesday, Benzinga reports. They presently have a $67.00 target price on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price target points to a potential upside of 79.05% from the stock’s previous close.

CLDX has been the topic of several other research reports. HC Wainwright reiterated a “buy” rating and issued a $80.00 price target on shares of Celldex Therapeutics in a report on Tuesday. Stifel Nicolaus initiated coverage on shares of Celldex Therapeutics in a research note on Tuesday, June 18th. They set a “buy” rating and a $58.00 price target for the company. Finally, Wolfe Research started coverage on shares of Celldex Therapeutics in a research note on Tuesday, June 11th. They issued an “outperform” rating and a $51.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $62.17.

Celldex Therapeutics Stock Down 10.9 %

NASDAQ:CLDX traded down $4.57 on Tuesday, reaching $37.42. The stock had a trading volume of 222,380 shares, compared to its average volume of 778,594. The stock has a fifty day moving average price of $36.74 and a 200-day moving average price of $39.19. Celldex Therapeutics has a 1-year low of $22.11 and a 1-year high of $53.18. The company has a market capitalization of $2.47 billion, a P/E ratio of -13.13 and a beta of 1.58.

Celldex Therapeutics (NASDAQ:CLDX) last announced its earnings results on Monday, May 6th. The biopharmaceutical company reported ($0.56) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.11. The company had revenue of $0.16 million for the quarter, compared to analyst estimates of $1.30 million. Celldex Therapeutics had a negative net margin of 2,385.57% and a negative return on equity of 29.55%. Sell-side analysts predict that Celldex Therapeutics will post -2.39 earnings per share for the current fiscal year.

Insider Activity

In other Celldex Therapeutics news, SVP Diane C. Young sold 45,000 shares of the company’s stock in a transaction that occurred on Friday, June 7th. The stock was sold at an average price of $35.26, for a total transaction of $1,586,700.00. Following the completion of the transaction, the senior vice president now owns 2,115 shares of the company’s stock, valued at approximately $74,574.90. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other Celldex Therapeutics news, SVP Diane C. Young sold 45,000 shares of the company’s stock in a transaction on Friday, June 7th. The shares were sold at an average price of $35.26, for a total value of $1,586,700.00. Following the transaction, the senior vice president now directly owns 2,115 shares in the company, valued at $74,574.90. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, VP Elizabeth Crowley sold 30,000 shares of the company’s stock in a transaction on Friday, June 14th. The shares were sold at an average price of $34.87, for a total value of $1,046,100.00. Following the completion of the transaction, the vice president now directly owns 9,074 shares in the company, valued at $316,410.38. The disclosure for this sale can be found here. Insiders have sold a total of 266,332 shares of company stock worth $9,155,821 over the last three months. Corporate insiders own 3.80% of the company’s stock.

Hedge Funds Weigh In On Celldex Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. Strs Ohio raised its stake in Celldex Therapeutics by 92.9% in the fourth quarter. Strs Ohio now owns 2,700 shares of the biopharmaceutical company’s stock valued at $107,000 after purchasing an additional 1,300 shares in the last quarter. Headlands Technologies LLC bought a new position in Celldex Therapeutics in the first quarter valued at approximately $147,000. CANADA LIFE ASSURANCE Co raised its position in Celldex Therapeutics by 26.4% during the first quarter. CANADA LIFE ASSURANCE Co now owns 4,570 shares of the biopharmaceutical company’s stock valued at $192,000 after purchasing an additional 955 shares in the last quarter. Ameritas Investment Partners Inc. lifted its stake in Celldex Therapeutics by 34.3% during the first quarter. Ameritas Investment Partners Inc. now owns 6,198 shares of the biopharmaceutical company’s stock worth $260,000 after purchasing an additional 1,582 shares during the last quarter. Finally, Aigen Investment Management LP acquired a new stake in shares of Celldex Therapeutics in the 4th quarter valued at $251,000.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.